LAGUNA HILLS, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it ...
LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone for DCISionRT®, its ...
DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit. Patients with DCIS have cancerous cells lining the milk ducts of ...
Tweet this DCISionRT ® is a precision medicine test for women diagnosed with DCIS (Ductal Carcinoma in situ) or Stage 0 breast cancer who are treated with breast-conserving surgery. The DCISionRT test ...
LAGUNA HILLS, Calif. , Dec. 8, 2020 /PRNewswire/ -- Prelude Corporation (PreludeDx ™ ), a leader in molecular diagnostics and precision medicine for early stage breast cancer, will present clinical ...
LAGUNA HILLS, Calif., March 28, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the ...
LAGUNA HILLS, Calif., Nov. 30, 2017 /PRNewswire/ -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, announced today that ...
Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is typically ...
LAGUNA HILLS, Calif., Dec. 15, 2020 /PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results